ANI Pharmaceuticals, Inc.
ANIP
$70.12
-$0.11-0.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 12.04% | -3.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.04% | -3.88% | |||
| Cost of Revenue | 7.03% | -6.67% | |||
| Gross Profit | 15.29% | -1.98% | |||
| SG&A Expenses | 24.45% | -10.49% | |||
| Depreciation & Amortization | -6.11% | -7.49% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.81% | -8.59% | |||
| Operating Income | 2.92% | 30.64% | |||
| Income Before Tax | -7.77% | 27.77% | |||
| Income Tax Expenses | 15.44% | 168.96% | |||
| Earnings from Continuing Operations | -16.21% | 7.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.21% | 7.28% | |||
| EBIT | 2.92% | 30.64% | |||
| EBITDA | -0.25% | 14.14% | |||
| EPS Basic | -17.11% | 6.86% | |||
| Normalized Basic EPS | 3.03% | 30.11% | |||
| EPS Diluted | -17.54% | 8.88% | |||
| Normalized Diluted EPS | 2.45% | 32.95% | |||
| Average Basic Shares Outstanding | 1.17% | 1.10% | |||
| Average Diluted Shares Outstanding | 1.72% | -1.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||